Director Dealing
Bioventix plc
("Bioventix" or "the Company")
Director Dealing
Bioventix plc (BVXP), a UK company specialising in the development and commercial supply of high-affinity monoclonal antibodies for applications in clinical diagnostics, announces the Company was notified that earlier today Bruce Hiscock, Chief Financial Officer of the Company, purchased a total of 534 ordinary shares of 5 pence each in the Company ("Ordinary Shares"), at a price of 1,799 pence per Ordinary Share (the "Purchase").
Following the Purchase, Bruce Hiscock has a beneficial interest in 2,200 Ordinary Shares, representing approximately 0.04 per cent. of the issued share capital of the Company.
The notification below, made in accordance with the requirements of the EU Market Abuse Regulation, provides further details.
For further information please contact:
Bioventix plc
Peter Harrison
Chief Executive Officer
Tel: 01252 728 001
Cavendish
Geoff Nash / Elysia Bough
Nigel Birks / Harriet Ward
Corporate Finance
ECM
Tel: 020 7220 0500
Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them
1
Details of the person discharging managerial responsibilities / person closely associated
a)
Name
Bruce Hiscock
2.
Reason for the Notification
a)
Position/status
Chief Financial Officer
b)
Initial notification/Amendment
Initial notification
3.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
Bioventix Plc
b)
LEI
213800225MHX7LZQY108
4.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)
Description of the Financial instrument, type of instrument
Ordinary Shares of 5 pence each
Identification code
GB00B4QVDF07
b)
Nature of the transaction
Purchase of Ordinary Shares
c)
Price(s) and volume(s)
534 Ordinary Shares
1,799 pence
d)
Aggregated information:
· Aggregated volume
· Price
Purchase of 534 Ordinary Shares at 1,799 pence each
e)
Date of the transaction
24 June 2026
f)
Place of the transaction
London Stock Exchange, AIM Market (XLON)
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.ENDDSHEALKLALXKEFA
